u.s. fda approves amgen’s targeted immunotherapy for adults w/extensive-stage small cell lung cancer
Published 6 months ago • 235 plays • Length 0:29Download video MP4
Download video MP3
Similar videos
-
0:37
amgen’s tarlatamab gets fda priority review for small cell lung cancer
-
0:17
oncologists have a new weapon in their arsenal to attack extensive-stage small cell lung cancer.
-
4:20
sotorasib,fda,lumakras amgen 510,non-small cell lung cancer
-
0:46
fda approves capmatinib for advanced lung cancer
-
5:10
fda approves lung cancer treatment option
-
0:48
immunotherapy for patients with small-cell lung cancer
-
8:36
emergence of immunotherapy for small cell lung cancer
-
2:52
immunotherapy treatments for small cell lung cancer (sclc)
-
0:58
deborah’s experience with non-small cell lung cancer
-
4:17
fda approves atezolizumab as adjuvant treatment for non-small cell lung cancer
-
3:50
charles’s journey with small cell lung cancer
-
27:08
immunotherapy advances in small cell lung cancer
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
0:46
3 common myths about lung cancer w/ dr. eric singhi
-
0:17
amgen's late-stage data for lung cancer drug 'not adequate' - fda staff|shorts
-
1:45
strategies to target her2 in lung cancer
-
1:27
fda approval of atezolizumab for nsclc
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
59:01
gene targeted therapy for non small cell lung cancer